2025 Q4 -tulosraportti
Vain PDF
25 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·25 min sittenhave a small lump of money. around 20 k have some some nice stocks I can put them in so that they get a good of nice start boost. yes I eat and choose sell but never wrong with input
·2 t sittenFor those who haven't seen investornytt's talk with Erik 10. April. https://www.youtube.com/live/92FiyAAduJw?si=UGQ5Cr-t5K3WMEF5&t=1390
·5 t sittenFollowing the latest mentions of Hantavirus, including its discovery in a closed environment such as a cruise ship, interest in new RNA platforms has once again begun to rise among both researchers and investors. This is not because the disease has suddenly become global, but because it reminds the market how quickly a rare virus can create a need for a vaccine and preparedness solution that can be developed extremely quickly. In this context, clear movements have been observed in the stock market, where Moderna experienced an upswing in connection with increased mention of their RNA platform and possible application in new infectious diseases, including hantavirus-related research. At the same time, Traws Pharma rose significantly following speculative interest in antiviral programs targeting rare zoonotic viruses, with hantavirus being mentioned as an example in the investment community. If one considers Circio's circVec platform with significantly higher and more sustained protein expression at a lower dose and simultaneously a better safety profile, it will have direct relevance in scenarios such as hantavirus preparedness. Not because the disease is global, but because it requires a platform that can react quickly and protect at-risk groups (frail, elderly, and already ill people) effectively without complex vaccination programs. This is precisely where Circio potentially positions itself differently from traditional mRNA players: not as a competitor for rapid vaccine production, but as a possible "extension technology" that can make immunity more durable and effective. Look back at Moderna and Pfizer's astronomical gains during the last pandemic. Now imagine a licensing agreement with royalties for Circio when using the platform in their vaccines. I see ONLY gigantic potential for Circio in the future. 💰
·9 t sittenIt is said that those who have made money on stock investments live by: Not restless and short-term but Calm and long-term. such as the largest shareholder in Circicio - Høse AS
·12 t sittenI just want to hear from the experienced ones. I myself have shares in circio. What happens after an acquisition? Will the acquiring company take circio over into theirs and we get shares there in their company. Or will circio continue as its own entity. With a higher share price. It is a serious question. As I am considering selling thereafter (before human trials)
·9 t sittenYes, but an important point is that with so many touchpoints, it won't just be one, but several who buy into the use of circio's product/s.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
25 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·25 min sittenhave a small lump of money. around 20 k have some some nice stocks I can put them in so that they get a good of nice start boost. yes I eat and choose sell but never wrong with input
- ·2 t sittenFor those who haven't seen investornytt's talk with Erik 10. April. https://www.youtube.com/live/92FiyAAduJw?si=UGQ5Cr-t5K3WMEF5&t=1390
- ·5 t sittenFollowing the latest mentions of Hantavirus, including its discovery in a closed environment such as a cruise ship, interest in new RNA platforms has once again begun to rise among both researchers and investors. This is not because the disease has suddenly become global, but because it reminds the market how quickly a rare virus can create a need for a vaccine and preparedness solution that can be developed extremely quickly. In this context, clear movements have been observed in the stock market, where Moderna experienced an upswing in connection with increased mention of their RNA platform and possible application in new infectious diseases, including hantavirus-related research. At the same time, Traws Pharma rose significantly following speculative interest in antiviral programs targeting rare zoonotic viruses, with hantavirus being mentioned as an example in the investment community. If one considers Circio's circVec platform with significantly higher and more sustained protein expression at a lower dose and simultaneously a better safety profile, it will have direct relevance in scenarios such as hantavirus preparedness. Not because the disease is global, but because it requires a platform that can react quickly and protect at-risk groups (frail, elderly, and already ill people) effectively without complex vaccination programs. This is precisely where Circio potentially positions itself differently from traditional mRNA players: not as a competitor for rapid vaccine production, but as a possible "extension technology" that can make immunity more durable and effective. Look back at Moderna and Pfizer's astronomical gains during the last pandemic. Now imagine a licensing agreement with royalties for Circio when using the platform in their vaccines. I see ONLY gigantic potential for Circio in the future. 💰
- ·9 t sittenIt is said that those who have made money on stock investments live by: Not restless and short-term but Calm and long-term. such as the largest shareholder in Circicio - Høse AS
- ·12 t sittenI just want to hear from the experienced ones. I myself have shares in circio. What happens after an acquisition? Will the acquiring company take circio over into theirs and we get shares there in their company. Or will circio continue as its own entity. With a higher share price. It is a serious question. As I am considering selling thereafter (before human trials)·9 t sittenYes, but an important point is that with so many touchpoints, it won't just be one, but several who buy into the use of circio's product/s.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
25 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·25 min sittenhave a small lump of money. around 20 k have some some nice stocks I can put them in so that they get a good of nice start boost. yes I eat and choose sell but never wrong with input
- ·2 t sittenFor those who haven't seen investornytt's talk with Erik 10. April. https://www.youtube.com/live/92FiyAAduJw?si=UGQ5Cr-t5K3WMEF5&t=1390
- ·5 t sittenFollowing the latest mentions of Hantavirus, including its discovery in a closed environment such as a cruise ship, interest in new RNA platforms has once again begun to rise among both researchers and investors. This is not because the disease has suddenly become global, but because it reminds the market how quickly a rare virus can create a need for a vaccine and preparedness solution that can be developed extremely quickly. In this context, clear movements have been observed in the stock market, where Moderna experienced an upswing in connection with increased mention of their RNA platform and possible application in new infectious diseases, including hantavirus-related research. At the same time, Traws Pharma rose significantly following speculative interest in antiviral programs targeting rare zoonotic viruses, with hantavirus being mentioned as an example in the investment community. If one considers Circio's circVec platform with significantly higher and more sustained protein expression at a lower dose and simultaneously a better safety profile, it will have direct relevance in scenarios such as hantavirus preparedness. Not because the disease is global, but because it requires a platform that can react quickly and protect at-risk groups (frail, elderly, and already ill people) effectively without complex vaccination programs. This is precisely where Circio potentially positions itself differently from traditional mRNA players: not as a competitor for rapid vaccine production, but as a possible "extension technology" that can make immunity more durable and effective. Look back at Moderna and Pfizer's astronomical gains during the last pandemic. Now imagine a licensing agreement with royalties for Circio when using the platform in their vaccines. I see ONLY gigantic potential for Circio in the future. 💰
- ·9 t sittenIt is said that those who have made money on stock investments live by: Not restless and short-term but Calm and long-term. such as the largest shareholder in Circicio - Høse AS
- ·12 t sittenI just want to hear from the experienced ones. I myself have shares in circio. What happens after an acquisition? Will the acquiring company take circio over into theirs and we get shares there in their company. Or will circio continue as its own entity. With a higher share price. It is a serious question. As I am considering selling thereafter (before human trials)·9 t sittenYes, but an important point is that with so many touchpoints, it won't just be one, but several who buy into the use of circio's product/s.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt